A Phase 2, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Assess the Safety and Efficacy of S-309309 in Obese Adults
Latest Information Update: 12 Jul 2024
At a glance
- Drugs S-309309 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Shionogi
Most Recent Events
- 28 Jun 2024 Status changed from active, no longer recruiting to completed.
- 27 Oct 2023 Status changed from recruiting to active, no longer recruiting.
- 30 Jun 2023 Status changed from not yet recruiting to recruiting.